MINERALYS THERAPEUTICS, INC. Sale of Stock, Consideration Received on Transaction
MINERALYS THERAPEUTICS, INC. (MLYS) reported Sale of Stock, Consideration Received on Transaction of $378.80 million for the 11-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Notes
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2024-03-21
- 2023-12-31: Sale of Stock, Consideration Received on Transaction 11 month $378.80M.
- 2023-06-30: Sale of Stock, Consideration Received on Transaction 4 month $378.80M.
- 2023-03-31: Sale of Stock, Consideration Received on Transaction 1 month $378.80M.
| Period end | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 4 month | Sale of Stock, Consideration Received on Transaction 11 month |
|---|---|---|---|
| 2023-12-31 | $378.80M 10-K · filed 2024-03-21 | ||
| 2023-06-30 | $378.80M 10-Q · filed 2023-11-07 | ||
| 2023-03-31 | $378.80M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |